Contraception Clinical Trial
Official title:
Progestin-Only Pill Use and Breastfeeding Study
Verified date | April 2024 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will assess the impact of early initiation (less than one week postpartum) and delayed initiation (4 weeks postpartum) of two types of progestin-only contraceptive pills (POPs) on maternal, breastmilk, and infant outcomes.
Status | Completed |
Enrollment | 30 |
Est. completion date | November 4, 2022 |
Est. primary completion date | November 4, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years of age and older - Desires to use POPs for 3 months - Speak English or Spanish - Had a vaginal or cesarean delivery of a singleton full term (=37 weeks) infant less than 168 hours prior - Intends to breastfeed exclusively for 6 months Exclusion Criteria: - Desire another pregnancy in less than 6 months - Do not intend to exclusively breastfeed - Do not have access to a telephone - Have any medical contraindication to POPs - Have any contraindication to breastfeeding, including maternal illegal drug use, history of augmentation or reduction, infant with major congenital anomaly - Cognitively impaired - Currently incarcerated |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Diego | La Jolla | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Diego |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Exclusive Lactation Among Birthing People at 8 Weeks Postpartum. | Lactation status will be assessed at 8 weeks postpartum through an email self-reported survey. | 8 weeks postpartum | |
Secondary | Proportion of Birthing People Using Progestin-only Pills at 8 Weeks Postpartum | Type of contraception being used at 8 weeks postpartum will be assessed through an email self-reported survey. | 8 weeks postpartum | |
Secondary | Vaginal Bleeding | Number of days of any bleeding and spotting among birthing people in last week will be collected via self-reported email survey. | 8 weeks postpartum | |
Secondary | Satisfaction With Assigned POP | Overall satisfaction and if birthing people would recommend the POP they were assigned to use to a friend will be ascertained from an email self-report survey. Counts are the number of birthing people who responded "yes". | 8 weeks postpartum | |
Secondary | Protein Content of Human Milk | Mid-feeding milk samples will be pumped by birthing people and analyzed. | 4 weeks postpartum | |
Secondary | Carbohydrate Content of Human Milk | Mid-feeding milk samples will be pumped by birthing people and analyzed. | 4 weeks postpartum | |
Secondary | Fat Content of Human Milk | Mid-feeding milk samples will be pumped by birthing people and analyzed. | 4 weeks postpartum | |
Secondary | Perception of Milk Supply | Self-reported perception of adequacy of milk supply will be collected with the 20-item Hill and Humenick Lactation Scale among birthing people. Minimum scale score is 20 and maximum is 140, with higher scores representing a more positive perception of breastfeeding. | 8 weeks postpartum | |
Secondary | Change in Infant Weight | Infant weight in grams will be compared over 4 weeks. | Baseline and 4 weeks after delivery | |
Secondary | Change in Infant Height | Infant length as measured on a marked board to the nearest millimeter will be compared over 4 weeks. | Baseline and 4 weeks after delivery | |
Secondary | Change in Infant Head Circumference | The maximum diameter through the infant's glabella and occiput is found and measured with a tape measure and recorded to the nearest millimeter and compared over 4 weeks. | Baseline and 4 weeks after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |